Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.68 |
| ▸ | CDK2 | P24941 | 3/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.55 |
| ▸ | IGF1R | P08069 | 6/20 | 0.53 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12878269 | 0.89 | CCNA2 (0.66) | CCNA2CDK2NTRK1IGF1RNUAK1 | |
| SCHEMBL12783910 | 0.89 | CCNA2 (0.54) | CCNA2CDK2NTRK1IGF1R | |
| SCHEMBL1164457 | 0.89 | CCNA2 (0.54) | CCNA2CDK2NTRK1IGF1R | |
| SCHEMBL12784897 | 0.88 | CCNA2 (0.65) | CCNA2CDK2NTRK1IGF1RNUAK1 | |
| SCHEMBL12878463 | 0.87 | CCNA2 (0.74) | CCNA2CDK2NTRK1IGF1R | |
| SCHEMBL12784885 | 0.87 | CCNA2 (0.64) | CCNA2CDK2NTRK1IGF1R | |
| SCHEMBL2069987 | 0.86 | CCNA2 (0.58) | CCNA2CDK2NTRK1IGF1R | |
| SCHEMBL12784671 | 0.85 | CCNA2 (0.64) | CCNA2CDK2NTRK1IGF1RNUAK1 | |
| SCHEMBL12878583 | 0.85 | CCNA2 (0.68) | CCNA2CDK2NTRK1IGF1R | |
| SCHEMBL12784874 | 0.85 | CCNA2 (0.71) | CCNA2CDK2NTRK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422271-B2 | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422271-B2 | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2464641-B1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMA (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | CCNA2 1047/4885CDK2 122/4885NTRK1 4659/4885 |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | CCNA2 1047/4885CDK2 122/4885NTRK1 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.